Eglonil is a product with a moderate antipsychotic effect, a slight antidepressant and stimulant effect. The antipsychotic effect of the product is achieved by selective blockade of dopamine receptors.
A dose of 0.15-0.6 g of sulpiride per day is effective in eliminating negative symptoms (anhedonia, apathy), but has practically no effect on productive symptoms (delusions, hallucinations). At a dose of 0.6–1.6 g per day, the product successfully eliminates productive symptoms, and at very large doses it has a slight sedative effect.
When administered intramuscularly, the maximum concentration of the product is reached after half an hour, when taken orally, after 4-4.5 hours. The drug has a linear pharmacokinetics, i.e. there is a direct relationship between the maximum concentration in the blood and the dose taken. The drug can penetrate the BBB, does not form active metabolites. It is excreted through the kidneys almost unchanged, the half-life is within 7 hours.
Eglonil (Eglonil) method of administration and doses:
At the beginning of treatment, the product is administered intramuscularly, then they switch to tablet intake.
In case of psychoses, the dose of the product is selected depending on which symptomatology is dominant: with the predominance of negative symptoms, the dose of Eglonil is 0.2-0.6 g per day, positive – 0.8-1.6 g per day. In other cases, the product is prescribed at a dose of 0.1 – 0.2 g. The
dose for babies is from 5 to 10 mg per kg of body weight per day, depending on the nosology and severity of symptoms.
Eglonil (Eglonil) side effects:
Sedation, sleep disturbances, increase or decrease in blood pressure, extrapyramidal disorders, (decrease under the influence of antiparkinsonian drugs), early and tardive dyskinesia, impotence, gynecomastia, menstrual disorders, galactorrhea, weight gain, decreased libido and frigidity.
Children born to mothers who took sulpiride at a dose of up to 0.2 g per day during pregnancy did not have malformations; there is no experience of using sulpiride in high doses in pregnant women. During pregnancy, it is recommended to reduce the dose of the product and reduce the treatment period to the minimum possible. After birth, children should be examined by a neurologist to rule out extrapyramidal disorders.
Symptoms: extrapyramidal disorders up to coma. Treatment: control of respiratory function and monitoring of cardiac activity (it is especially necessary to control the QT interval), in some cases resuscitation, hemodialysis and antiparkinsonian drugs are necessary.
Use with other drugs:
During therapy with sulpiride, it is necessary to avoid the use of alcohol and alcohol-containing products, due to the potentiation of the sedative effect.
Levodopa and sulpiride have a mutual antagonistic effect, so the simultaneous use of these products is not recommended.
Antihypertensive products may increase the risk of hypotension and postural hypotension.
Tranquilizers, barbiturates, morphine derivatives, benzodiazepines can increase the inhibitory effect on the central nervous system.
Capsules 50 mg, in a pack of 30 capsules.
Tablets, divisible 200 mg, in a pack of 12 tablets.
Tablets divided into 200 mg, in a pack of 60 tablets.
5% solution in ampoules of 2 ml (100 mg per ampoule) No. 6.
Tablets 200 mg
Active substance: sulpiride 200 mg.
Additional substances: lactose, methylcellulose, potato starch, silicon dioxide, talc, magnesium stearate.
Solution for injection
Active substance: sulpiride 100 mg.
Additional substances: sulfuric acid, sodium chloride, prepared water.
If the temperature rises, it is necessary to cancel the product, since hyperthermia can be a symptom of neuroleptic malignant syndrome, this is especially true when using the product in large doses.
Eglonil should be administered with caution to elderly and senile patients, patients with renal insufficiency, such patients sometimes require a dose reduction of the product.
In patients with epilepsy, Eglonil may reduce the threshold for convulsive readiness, therefore, when using the product, careful monitoring of the patient’s condition is required.
For patients suffering from Parkinson’s disease, Eglonil is prescribed according to strict indications.
Eglonil has the ability to penetrate into breast milk, therefore, when taking the product, it is necessary to refuse breastfeeding.
Since the product causes drowsiness, it should be administered with caution to drivers of vehicles and people working with complex mechanisms.